Praxis Q3 net loss $51.9M; relutrigine seizure freedom; ulixacaltamide interim Q1 2025

Praxis Precision Medicines, Inc.

2024-Q3 EPS reported -$7.21 revenue$1,090,000

Cash and equivalents $411.2M at Sep 30, 2024, up from $81.3M at Dec 31, 2023; net loss $51.9M vs $24.6M prior year Q3.
Relutrigine (PRAX-562): 46% placebo-adjusted seizure reduction in EMBOLD cohort 1; 30% of patients (5/15) achieved seizure freedom; registrational cohort 2 initiated.
Ulixacaltamide: interim analysis for Phase 3 Essential3 Study 1 expected Q1 2025; NDA filing anticipated in 2025; Parkinson's program to re-initiate.
Vormatrigine (PRAX-628): RADIANT topline in H1 2025 and POWER1 topline in H2 2025; pain expansion being evaluated.
R&D expenses $41.9M (up $24.6M); G&A $15.3M (up $6.6M); stock-based compensation $12.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.